Roche defends 6B franc Vabysmo peak target despite another miss
Roche’s Vabysmo disappointed investors again. In the second quarter, the eye drug’s sales of about 1.04 billion Swiss…
Roche FDA accepts Lunsumio-Polivy lymphoma sBLA
Roche (OTCQX:RHHBY) reported that the FDA has accepted a supplemental Biologics License Application…
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
F. Hoffmann-La Roche Ltd Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory…
Roche: Lunsumio combo hits 87.0% CR in follicular lymphoma
Roche (OTCQX: RHHBY) presented data at ASH 2025 showing Lunsumio (mosunetuzumab) combinations may…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
Roche to Present 46 Abstracts, 12 Orals at ASH Meeting
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…
Roche Receives Conditional Authorisation for Lunsumio SC
Roche (OTCQX: RHHBY) announced the European Commission granted conditional marketing authorisation for Lunsumio…